Tag: Cancer: Kidney

GAGome score had 90 percent sensitivity, 51 percent specificity for radiological recurrence, with AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma

Higher weighted years with overweight/obesity linked to increased risk for overall, aggressive, fatal, and clear-cell renal cell carcinoma

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma

Findings seen for 240 counties in Texas when accounting for demographic, socioeconomic factors and cancer risk factors

In a recent study, mean sensitivity was 85.5 percent and specificity 87 percent for detection of clear-cell renal cell carcinoma

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting

Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer

Belzutifan beneficial for advanced clear cell renal cell carcinoma patients who had previously received immune checkpoint, antiangiogenic therapies

Validated polygenic risk score generated, with area under the curve of 0.65 among European ancestry individuals

Disease-free survival benefit was consistent with that seen in previous analyses; improvement in overall survival also seen